Company / CapEx per Share
CRISPR Therapeutics AG CapEx per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.01
FY2025
5-year range
$0.01 / $1.06
FY2021-FY2025
Trend
-57.0%
vs FY2024
Sector context
#127 of 193
Health Care
What the data says
At $0.01, CRISPR Therapeutics AG's capex per share ranks #127 of 193 in the Health Care sector. CapEx per Share has declined for 4 consecutive years, from $1.06 in FY2021 to $0.01 in FY2025.
Based on SEC 10-K filings.
0.01 in FY2025 with a 5-year CAGR of -47.9%.
Declined from $0.12 to $0.01 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- -72.8%
- 5-Year CAGR
- -47.9%
- 10-Year CAGR
- -
Sector benchmark
#127 of 193 in Health CareTop 66% of 193This company $0.01 Sector average $3.52
▼
-99.7% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's capex per share has declined for 4 consecutive years.
- In FY2025, capex per share decreased 57.0% year-over-year.
- Ranks #127 out of 193 companies in the Health Care sector.
- Peak capex per share was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.01 | -57.0% |
| FY2024 | $0.02 | -81.3% |
| FY2023 | $0.12 | -75.0% |
| FY2022 | $0.47 | -55.4% |
| FY2021 | $1.06 | +327.3% |
| FY2020 | $0.25 | +92.7% |
| FY2019 | $0.13 | +73.5% |
| FY2018 | $0.07 | +155.7% |
| FY2017 | $0.03 | -86.1% |
| FY2016 | $0.21 | -8.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026